IMRiS, a phase II study of Intensity Modulated Radiotherapy in Sarcoma

Researchers at UCLH will be leading on the IMRiS trial, a UK national phase II study of intensity modulated radiotherapy (IMRT) in sarcoma. IMRT is an advanced radiotherapy technique that has the potential to reduce the radiation dose to the normal body tissues in the treatment area. This effect may have an impact on reducing the immediate and long term side effects of treatment. It could also allow higher doses of radiation to be given safely to bone sarcomas in the spine and pelvis. The trial will look at 3 groups of sarcoma patients: those with soft tissue sarcomas of the limbs, Ewing sarcoma of the spine or pelvis, and other bone sarcomas/chordoma in the spine or pelvis.

The trial is funded by Cancer Research UK. Dr Beatrice Seddon is the lead investigator for the trial.

For more information:

UK Clinical Research Network Study Portfolio (http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=19629)

US National Institute of Health (https://clinicaltrials.gov/ct2/show/NCT02520128)

< Back